{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:02:39Z","timestamp":1789657359981,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003010","name":"Ege University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003010","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Despite the success of immune checkpoint inhibitors (ICIs) in metastatic melanoma, many patients fail to derive meaningful benefit, underscoring the urgent need for accessible prognostic biomarkers. The C-reactive protein (CRP)\u2013albumin\u2013lymphocyte (CALLY) index, an immunonutritional index, has shown prognostic value in various cancers. Previous studies indicate that systemic inflammation and nutritional status influence ICI efficacy, suggesting the potential relevance of the CALLY index in metastatic melanoma. This study evaluates the CALLY index\u2019s role in metastatic melanoma patients treated with anti-PD-1 therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study analysed 92 patients with metastatic melanoma who were treated with anti-PD-1 monotherapy at Ege University\u2019s Faculty of Medicine between 2015 and 2023. The CALLY index was calculated using the pre-treatment CRP, albumin and lymphocyte levels. Kaplan\u2013Meier analysis was used to estimate survival outcomes, and univariate and multivariate Cox regression models were employed to identify independent prognostic factors. A predictive nomogram incorporating the CALLY index and other significant variables was then developed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The optimal CALLY index cutoff was determined to be 2. Patients with a low CALLY index (\u2264\u20092) had worse median overall survival (OS) and progression-free survival (PFS) when compared with those who had a high CALLY index (&gt;\u20092) (median OS: 9.6 vs 31.3\u00a0months, p\u2009&lt;\u20090.001; median PFS: 3.8 vs 10.6\u00a0months, p\u2009=\u20090.001). Multivariate analysis identified the CALLY index, lactate dehydrogenase above the upper limit of normal, Eastern Cooperative Oncology Group score\u2009\u2265\u20092, M1c\/M1d staging and acral\/mucosal melanoma subtypes to be independent predictors of OS. A nomogram was then constructed based on these factors, yielding a concordance index of 0.705 (95% confidence interval: 0.634\u20130.776). This model stratified patients into low-, intermediate- and high-risk groups, with the high-risk group showing significantly worse OS than the intermediate- and the low-risk groups (p\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The CALLY index is a cost-effective and independent prognostic biomarker that can aid in risk stratification and guide treatment decisions in patients with metastatic melanoma receiving anti-PD-1 therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12094-025-03888-z","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T13:02:41Z","timestamp":1742130161000},"page":"3770-3780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Prognostic utility of the CALLY index in metastatic melanoma: building a nomogram for Patients on Anti-PD-1 therapy"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9782-6807","authenticated-orcid":false,"given":"Caner","family":"Acar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-2983","authenticated-orcid":false,"given":"Haydar \u00c7a\u011fatay","family":"Y\u00fcksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-9383","authenticated-orcid":false,"given":"G\u00f6khan","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2749-8732","authenticated-orcid":false,"given":"Fatma Pinar","family":"A\u00e7ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-2021","authenticated-orcid":false,"given":"Damla","family":"Gunenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2638-1625","authenticated-orcid":false,"given":"Bur\u00e7ak","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,16]]},"reference":[{"key":"3888_CR1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2407417","author":"JD Wolchok","year":"2024","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMOA2407417.","journal-title":"N Engl J Med"},{"key":"3888_CR2","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1200\/JCO.21.01701","volume":"40","author":"IP Da Silva","year":"2022","unstructured":"Da Silva IP, Ahmed T, McQuade JL, et al. Clinical models to define response and survival with anti-PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma. J Clin Oncol. 2022;40:1068\u201380. https:\/\/doi.org\/10.1200\/JCO.21.01701.","journal-title":"J Clin Oncol"},{"key":"3888_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40:127\u201337. https:\/\/doi.org\/10.1200\/JCO.21.02229.","journal-title":"J Clin Oncol"},{"key":"3888_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/NATURE25187","volume":"553","author":"Z Eroglu","year":"2018","unstructured":"Eroglu Z, Zaretsky JM, Hu-Lieskovan S, et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018;553:347\u201350. https:\/\/doi.org\/10.1038\/NATURE25187.","journal-title":"Nature"},{"key":"3888_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, Lee SJ, Chmielowski B, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced braf-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41:186\u201397. https:\/\/doi.org\/10.1200\/JCO.22.01763.","journal-title":"J Clin Oncol"},{"key":"3888_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES10092135","author":"K Kudura","year":"2022","unstructured":"Kudura K, Nussbaumer L, Foerster R, Basler L. Inflammatory blood parameters as biomarkers for response to immune checkpoint inhibition in metastatic melanoma patients. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/BIOMEDICINES10092135.","journal-title":"Biomedicines"},{"key":"3888_CR7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/S41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K, et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24:498\u2013512. https:\/\/doi.org\/10.1038\/S41568-024-00705-7.","journal-title":"Nat Rev Cancer"},{"key":"3888_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-022-35096-6","author":"Q Sui","year":"2022","unstructured":"Sui Q, Zhang X, Chen C, et al. Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer. Nat Commun. 2022. https:\/\/doi.org\/10.1038\/S41467-022-35096-6.","journal-title":"Nat Commun"},{"key":"3888_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2020-001674","author":"P Johannet","year":"2020","unstructured":"Johannet P, Sawyers A, Qian Y, et al. Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/JITC-2020-001674.","journal-title":"J Immunother Cancer"},{"key":"3888_CR10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/S10147-019-01461-7","volume":"24","author":"C Mirili","year":"2019","unstructured":"Mirili C, Y\u0131lmaz A, Demirkan S, et al. Clinical significance of prognostic nutritional index (PNI) in malignant melanoma. Int J Clin Oncol. 2019;24:1301\u201310. https:\/\/doi.org\/10.1007\/S10147-019-01461-7.","journal-title":"Int J Clin Oncol"},{"key":"3888_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00432-023-05529-W\/TABLES\/4","volume":"150","author":"B Bilgin","year":"2024","unstructured":"Bilgin B, Kuralay Y, Yucel S. Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation. J Cancer Res Clin Oncol. 2024;150:1\u20137. https:\/\/doi.org\/10.1007\/S00432-023-05529-W\/TABLES\/4.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3888_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/J.HPB.2021.06.414","volume":"24","author":"H Iida","year":"2022","unstructured":"Iida H, Tani M, Komeda K, et al. Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma. HPB (Oxford). 2022;24:101\u201315. https:\/\/doi.org\/10.1016\/J.HPB.2021.06.414.","journal-title":"HPB (Oxford)"},{"key":"3888_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13195018","author":"L M\u00fcller","year":"2021","unstructured":"M\u00fcller L, Hahn F, M\u00e4hringer-kunz A, et al. Immunonutritive scoring for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: evaluation of the CALLY index. Cancers. 2021. https:\/\/doi.org\/10.3390\/CANCERS13195018.","journal-title":"Cancers"},{"key":"3888_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/JJCO\/HYAB157","volume":"52","author":"K Ueda","year":"2022","unstructured":"Ueda K, Suekane S, Kurose H, et al. Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab. Jpn J Clin Oncol. 2022;52:179\u201386. https:\/\/doi.org\/10.1093\/JJCO\/HYAB157.","journal-title":"Jpn J Clin Oncol"},{"key":"3888_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14133282","author":"D Tomsitz","year":"2022","unstructured":"Tomsitz D, Schlaak M, Zierold S, et al. Development of lymphopenia during therapy with immune checkpoint inhibitors is associated with poor outcome in metastatic cutaneous melanoma. Cancers. 2022. https:\/\/doi.org\/10.3390\/CANCERS14133282.","journal-title":"Cancers"},{"key":"3888_CR16","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1007\/S00432-021-03878-Y","volume":"148","author":"L Susok","year":"2022","unstructured":"Susok L, Said S, Reinert D, et al. The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy. J Cancer Res Clin Oncol. 2022;148:3103\u20138. https:\/\/doi.org\/10.1007\/S00432-021-03878-Y.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3888_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/CAS.13433","volume":"109","author":"H Tsukamoto","year":"2018","unstructured":"Tsukamoto H, Fujieda K, Senju S, et al. Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity. Cancer Sci. 2018;109:523\u201330. https:\/\/doi.org\/10.1111\/CAS.13433.","journal-title":"Cancer Sci"},{"key":"3888_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2020-000842","volume":"8","author":"AS Laino","year":"2020","unstructured":"Laino AS, Woods D, Vassallo M, et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020;8: e000842. https:\/\/doi.org\/10.1136\/JITC-2020-000842.","journal-title":"J Immunother Cancer"},{"key":"3888_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2019-000234","author":"T Yoshida","year":"2020","unstructured":"Yoshida T, Ichikawa J, Giuroiu I, et al. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/JITC-2019-000234.","journal-title":"J Immunother Cancer"},{"key":"3888_CR20","doi-asserted-by":"publisher","first-page":"48487","DOI":"10.1074\/JBC.R400025200","volume":"279","author":"S Black","year":"2004","unstructured":"Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279:48487\u201390. https:\/\/doi.org\/10.1074\/JBC.R400025200.","journal-title":"J Biol Chem"},{"key":"3888_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CANCERS13020168","volume":"13","author":"G Awada","year":"2021","unstructured":"Awada G, Jansen Y, Schwarze JK, et al. A comprehensive analysis of baseline clinical characteristics and biomarkers associated with outcome in advanced melanoma patients treated with pembrolizumab. Cancers (Basel). 2021;13:1\u201318. https:\/\/doi.org\/10.3390\/CANCERS13020168.","journal-title":"Cancers (Basel)"},{"key":"3888_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3254017","author":"A Utariani","year":"2020","unstructured":"Utariani A, Rahardjo E, Perdanakusuma DS. Effects of albumin infusion on serum levels of albumin, proinflammatory cytokines (TNF- \u03b1, IL-1, and IL-6), CRP, and MMP-8; tissue expression of EGRF, ERK1, ERK2, TGF- \u03b2, Collagen, and MMP-8; and wound healing in sprague dawley rats. Int J Inflam. 2020. https:\/\/doi.org\/10.1155\/2020\/3254017.","journal-title":"Int J Inflam"},{"key":"3888_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/FMOLB.2022.1039121","author":"DC Guven","year":"2022","unstructured":"Guven DC, Sahin TK, Erul E, et al. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front Mol Biosci. 2022. https:\/\/doi.org\/10.3389\/FMOLB.2022.1039121.","journal-title":"Front Mol Biosci"},{"key":"3888_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/S00595-024-02921-Y","author":"J Li","year":"2024","unstructured":"Li J, Zhang S, Hu X, et al. Correlation between the C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index and the prognosis of gastric cancer patients after gastrectomy: a systematic review and meta-analysis. Surg Today. 2024. https:\/\/doi.org\/10.1007\/S00595-024-02921-Y.","journal-title":"Surg Today"},{"key":"3888_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/CNCR.31778","volume":"125","author":"MA Bilen","year":"2019","unstructured":"Bilen MA, Martini DJ, Liu Y, et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer. 2019;125:127\u201334. https:\/\/doi.org\/10.1002\/CNCR.31778.","journal-title":"Cancer"},{"key":"3888_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES11030749","author":"T Mesti","year":"2023","unstructured":"Mesti T, Gra\u0161i\u010dKuhar C, Ocvirk J. Biomarkers for outcome in metastatic melanoma in first line treatment with immune checkpoint inhibitors. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/BIOMEDICINES11030749.","journal-title":"Biomedicines"},{"key":"3888_CR27","doi-asserted-by":"publisher","first-page":"e879","DOI":"10.1111\/JDV.17533","volume":"35","author":"N Pflug","year":"2021","unstructured":"Pflug N, Vitus M, Knuever J, et al. Treatment-specific evaluation of the modified Glasgow-Prognostic-Score in patients with advanced cutaneous melanoma. J Eur Acad Dermatol Venereol. 2021;35:e879\u201383. https:\/\/doi.org\/10.1111\/JDV.17533.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3888_CR28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/EXD.14725","volume":"32","author":"T Mori","year":"2023","unstructured":"Mori T, Izumi T, Doi R, et al. Immune checkpoint inhibitor-based therapy for advanced acral and mucosal melanoma. Exp Dermatol. 2023;32:276\u201389. https:\/\/doi.org\/10.1111\/EXD.14725.","journal-title":"Exp Dermatol"},{"key":"3888_CR29","doi-asserted-by":"publisher","first-page":"7695","DOI":"10.3390\/CURRONCOL29100608","volume":"29","author":"S Goutam","year":"2022","unstructured":"Goutam S, Stukalin I, Ewanchuk B, et al. Clinical factors associated with long-term survival in metastatic melanoma treated with anti-PD1 alone or in combination with ipilimumab. Curr Oncol. 2022;29:7695\u2013704. https:\/\/doi.org\/10.3390\/CURRONCOL29100608.","journal-title":"Curr Oncol"},{"key":"3888_CR30","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/annonc\/mdw016","volume":"27","author":"PF Ferrucci","year":"2016","unstructured":"Ferrucci PF, Ascierto PA, Pigozzo J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016;27:732\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw016.","journal-title":"Ann Oncol"},{"key":"3888_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/CMR.0B013E3283550AA5","volume":"22","author":"L Hoejberg","year":"2012","unstructured":"Hoejberg L, Bastholt L, Johansen JS, et al. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res. 2012;22:287\u201393. https:\/\/doi.org\/10.1097\/CMR.0B013E3283550AA5.","journal-title":"Melanoma Res"},{"key":"3888_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/01635581.2019.1634217","volume":"72","author":"DH Bicakli","year":"2020","unstructured":"Bicakli DH, Uslu R, G\u00fcney SC, Coker A. The relationship between nutritional status, performance status, and survival among pancreatic cancer patients. Nutr Cancer. 2020;72:202\u20138. https:\/\/doi.org\/10.1080\/01635581.2019.1634217.","journal-title":"Nutr Cancer"},{"key":"3888_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2023-006947","author":"AC Pavlick","year":"2023","unstructured":"Pavlick AC, Ariyan CE, Buchbinder EI, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/JITC-2023-006947.","journal-title":"J Immunother Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03888-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03888-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03888-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T08:02:39Z","timestamp":1756886559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03888-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,16]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["3888"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03888-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,16]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The Institutional Ethical Review Board of Ege University Hospital approved this study (24\u201312.1\u00a0T\/60). Given that this real-world study involved retrospectively collected data, the requirement for individual consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}